Unlearn.AI
AI platform for creating Digital Twins in clinical trials.
Uses disease-specific machine learning models to generate virtual placebo patients (Digital Twins). This accelerates clinical trials by supplementing control groups, enabling smaller, faster, and more ethical study designs.
PROS
- + Significantly reduces patient enrollment requirements (by 25-50%)
- + accelerates trial timelines and reduces overall costs
- + regulatory acceptance for pivotal studies by both EMA and FDA
- + allows for more ethical study designs by reducing the need for placebo control patients
- + enhances decision-making with real-time predictive insights and subgroup analysis.
CONS
- - Pricing is custom enterprise and not publicly disclosed (contact for pricing)
- - may require significant integration efforts with existing clinical trial infrastructures
- - performance is dependent on the quality and completeness of historical input data.
-
Reducing control group size in Phase 2/3 trials
-
optimizing clinical trial protocol design (endpoints
-
eligibility)
-
conducting real-time interim analyses to support faster decision-making
-
generating external comparators for single-arm or open-label studies
-
forecasting individual patient disease progression under standard of care.
SIMILAR TOOLS
Claude Healthcare
Claude helps healthcare organizations move faster without sacrificing accuracy, safety, or compliance. Less administrative work, more time with the people you serve.
ChatGPT Health
A dedicated experience in ChatGPT designed for health and wellness.
Verily
Precision health platform for research and patient care.
Medtronic (AI Surgery & Diabetes)
AI integrated into surgical robotics and chronic disease.